#USA #Boston #AI Assistant #ACTO #LAICA

ACTO Introduces Next-Generation LAICA™

At the recent Veeva Commercial Summit in Boston, ACTO, a prominent technology partner of Veeva, announced the upcoming arrival of LAICA™ (Life Sciences AI Conversational Assistant), an advanced AI-driven knowledge assistant tailored for pharmaceutical field teams. This cutting-edge tool aims to redefine how field professionals prepare for meetings and engage with healthcare providers (HCPs), ensuring they have the necessary information and confidence to make impactful conversations.

A Leap Forward in Pharma Technology

LAICA's next iteration introduces a sophisticated level of personalization and intelligence to support pharmaceutical representatives in navigating their interactions. Imagine a situation where a field representative is about to meet with a doctor who possesses over 15 years of experience in a therapeutic area; just before stepping into the clinic, LAICA can provide quick access to essential information and insights, empowering the rep to make a lasting impression with their HCP interaction.

Parth Khanna, CEO of ACTO, noted the pivotal role that AI plays in evolving the capabilities of such tools. He emphasized, "When we introduced LAICA three years ago, it marked a transformation in the knowledge access of field teams. The evolution of AI allows LAICA to learn continuously, adapting to the ever-changing landscape of pharmaceutical interactions." This adaptability ensures that LAICA meets representatives exactly where they are, aligning its support with their unique needs and motivations.

Enhanced Knowledge Ecosystem

The forthcoming version of LAICA will include multiple connectors to accessible, pre-approved content and data sources. This includes promotional materials, scientific content from Veeva Vault PromoMats, and real-time insights regarding customer needs. These enhancements significantly amplify LAICA's cognitive capabilities, enabling it to process intricate information and deliver precise answers that adhere to compliance regulations.

Moreover, LAICA will also enhance its emotional intelligence. By integrating user-specific data—including each field professional's training outcomes and confidence levels—the AI will adapt its responses. This customization will facilitate tailored suggestions, empowering representatives to delve deeper into crucial topics and enhance their preparation for HCP discussions.

Lisa Dreher, Director of National Sales Training at Currax Pharmaceuticals, expressed optimism about the impact of LAICA: "The ultimate goal is to facilitate meaningful, personalized interactions with HCPs. LAICA enables field professionals to access the right knowledge fast, which elevates the quality of every engagement and enhances pre-call strategies."

Experience LAICA in Action

Field professionals can witness LAICA in action at the ACTO booth during the Veeva Commercial Summit, happening from May 13-14, 2025. For those interested in exploring more about LAICA and ACTO's offerings, visiting their official website at www.acto.com or following them on LinkedIn will provide the latest updates and company news.

About ACTO

ACTO operates as an AI-backed Intelligent Field Excellence (IFE) platform focused on the life sciences sector. The platform aids sales, marketing, and medical teams in enhancing customer engagement and brand performance. By transforming field professionals into authoritative figures interacting with HCPs, ACTO ensures that they deliver relevant messaging while offering key insights to senior leaders for continuous improvement. With compliance to FDA 21 CFR Part 11 and certification under SOC 2 Type II, ACTO is recognized as a leading partner in the Life Sciences industry for intelligent field excellence.

In conclusion, the launch of LAICA™ is poised to significantly enhance the pharmaceutical environment, aiding field teams in becoming more effective and confident in their engagements and ultimately refining their interactions within the healthcare landscape.